Literature DB >> 23700045

IL-32, a potential therapeutic target for rheumatoid arthritis?

Qiang Xie1, Cheng Huang, Jian Zhong, Wen-Wen Shen, Shi-Cun Wang, Jun Li.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23700045     DOI： 10.1007/s00296-013-2780-6

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN： 0172-8172            Impact factor:   2.631


× No keyword cloud information.
  9 in total

1.  Tumour necrosis factor alpha-driven IL-32 expression in rheumatoid arthritis synovial tissue amplifies an inflammatory cascade.

Authors:  Bas Heinhuis; Marije I Koenders; Piet L van Riel; Fons A van de Loo; Charles A Dinarello; Mihai G Netea; Wim B van den Berg; Leo A B Joosten
Journal:  Ann Rheum Dis       Date:  2010-12-27       Impact factor: 19.103

2.  Tumor necrosis factor blockade differentially affects innate inflammatory and Th17 cytokines in rheumatoid arthritis.

Authors:  Sladjana M Zivojinovic; Nada N Pejnovic; Mirjana N Sefik-Bukilica; Ljiljana V Kovacevic; Ivan I Soldatovic; Nemanja S Damjanov
Journal:  J Rheumatol       Date:  2011-12-01       Impact factor: 4.666

3.  IL-32gamma induces the maturation of dendritic cells with Th1- and Th17-polarizing ability through enhanced IL-12 and IL-6 production.

Authors:  Mi Young Jung; Mi Hye Son; Soo Hyun Kim; Daeho Cho; Tae Sung Kim
Journal:  J Immunol       Date:  2011-05-06       Impact factor: 5.422

4.  Inflammation-dependent secretion and splicing of IL-32{gamma} in rheumatoid arthritis.

Authors:  Bas Heinhuis; Marije I Koenders; Fons A van de Loo; Mihai G Netea; Wim B van den Berg; Leo A B Joosten
Journal:  Proc Natl Acad Sci U S A       Date:  2011-03-07       Impact factor: 11.205

5.  IL-32 aggravates synovial inflammation and bone destruction and increases synovial natural killer cells in experimental arthritis models.

Authors:  Young-Eun Park; Geun-Tae Kim; Seung-Geun Lee; Seong-Hu Park; Seung-Hoon Baek; Sung-Il Kim; Ju-In Kim; Hua-Shu Jin
Journal:  Rheumatol Int       Date:  2012-04-19       Impact factor: 2.631

6.  IL-32, a proinflammatory cytokine in rheumatoid arthritis.

Authors:  Leo A B Joosten; Mihai G Netea; Soo-Hyun Kim; Do-Young Yoon; Birgitte Oppers-Walgreen; Timothy R D Radstake; Pilar Barrera; Fons A J van de Loo; Charles A Dinarello; Wim B van den Berg
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-21       Impact factor: 11.205

7.  Tumor necrosis factor alpha-induced interleukin-32 is positively regulated via the Syk/protein kinase Cdelta/JNK pathway in rheumatoid synovial fibroblasts.

Authors:  Se Hwan Mun; Jie Wan Kim; Seong Su Nah; Na Young Ko; Jun Ho Lee; Ju Dong Kim; Do Kyun Kim; Hyuk Soon Kim; Ji Da Choi; Soo Hyun Kim; Chang Keun Lee; Seung Hwa Park; Bo Kyung Kim; Hyung Sik Kim; Young Mi Kim; Wahn Soo Choi
Journal:  Arthritis Rheum       Date:  2009-03

8.  Enhanced susceptibility to lipopolysaccharide-induced arthritis and endotoxin shock in interleukin-32 alpha transgenic mice through induction of tumor necrosis factor alpha.

Authors:  Masanori Nakayama; Yasuo Niki; Toshiki Kawasaki; Yuki Takeda; Keisuke Horiuchi; Aya Sasaki; Yasunori Okada; Kazuo Umezawa; Hiroyasu Ikegami; Yoshiaki Toyama; Takeshi Miyamoto
Journal:  Arthritis Res Ther       Date:  2012-05-21       Impact factor: 5.156

9.  Interactions between IL-32 and tumor necrosis factor alpha contribute to the exacerbation of immune-inflammatory diseases.

Authors:  Hirofumi Shoda; Keishi Fujio; Yumi Yamaguchi; Akiko Okamoto; Tetsuji Sawada; Yuta Kochi; Kazuhiko Yamamoto
Journal:  Arthritis Res Ther       Date:  2006       Impact factor: 5.156
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.